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accelerate time to remission, and overcome single agent resistance are of considerable interest. We have previously shown that the XPO1 inhibitor selinexor is pro-apoptotic in CLL cells and disrupts BCR signaling via BTK depletion. Herein we show the combination of selinexor and ibrutinib elicits a synergistic cytotoxic effect in primary CLL cells. The combination increases overall survival compared to ibrutinib alone in a mouse model of CLL. Selinexor is effective in cells isolated from patients with prolonged lymphocytosis following ibrutinib therapy. Finally, selinexor is effective in ibrutinibrefractory mice and in a cell line harboring the BTK C481S mutation. This is the first report describing the combined activity of ibrutinib and selinexor in CLL, which represents a new treatment paradigm and warrants further evaluation in clinical trials of CLL patients including those with acquired ibrutinib resistance.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a lymphoid malignancy of clonal B-cells that exhibit aberrant activation of the B-cell receptor (BCR) signaling pathway. A critical component of this pathway is Bruton agammaglobulinemia tyrosine kinase (BTK), a nonreceptor tyrosine kinase expressed predominantly in B-lymphocytes 3 . Ibrutinib, which irreversibly binds and inhibits BTK activity, has shown promising results in CLL, MCL, and a subset of DLBCL driven by BCR signaling [4] [5] [6] Exportin-1 (CRM1/XPO1) is the sole nuclear exporter of tumor suppressor proteins such as p53, IkB, and FOXO3a 9, 10 . Selective inhibitors of nuclear export (SINEs) inhibit XPO1 and restore subcellular localization of dysregulated molecules. Our previous published work showed XPO1 is a therapeutic target for CLL 11 , and has facilitated translation of selinexor, a SINE, to a Phase I clinical trial (NCT01607892)
where anti-tumor activity has been observed in lymphoma 12 , CLL 12 , multiple myeloma 13 , and acute myeloid leukemia 14 . We recently showed that selinexor inhibits activation of downstream BCR targets such as ERK and AKT and suppresses BTK gene expression 15 . Based on these observations, we hypothesized that i) targeting XPO1 via selinexor might be effective in patients with acquired resistance to ibrutinib, and ii) dual targeting of XPO1 alongside BTK function might produce synergistic activity in CLL and prevent onset of ibrutinib-resistant clones.
METHODS
For personal use only. on October 15, 2017 . by guest www.bloodjournal.org From Human CLL and normal B-cells were isolated and cultured as previously described 11 .
Blood was obtained from CLL patients under an IRB-approved protocol with informed consent according to the Declaration of Helsinki. Cell death was assessed using either Annexin-V/PI staining as previously described 11 . Chicken DT40 BTK null cell lines (RCB1468) were obtained from the Riken bioresource, Japan. Lentiviral constructs pReceiver-LV125 and A0534-Lv125 were obtained from Genecopoeia and were used to For personal use only. on October 15, 2017. by guest www.bloodjournal.org From described models 11 . Selinexor was provided by Karyopharm, Inc. Ibrutinib for in vivo studies was provided by Pharmacyclics, Inc. and for in vitro studies was purchased from Selleck.
RESULTS AND DISCUSSION
We have previously shown that selinexor exhibits pro-apoptotic activity against CLL cells via inhibition of nuclear export of tumor suppressor proteins 11 . Additionally we have
shown that selinexor counteracts BCR signaling partially through the down-modulation of BTK protein expression 15 . We therefore hypothesized selinexor would synergize with ibrutinib as it targets BTK through a completely different mechanism. We examined this hypothesis in primary CLL patient samples and found that ibrutinib and selinexor in combination exhibit significant synergistic cytotoxicity ( Figure 1A ). We repeated this assay in patient samples stimulated via TLR9 using synthetic CpG For personal use only. on October 15, 2017. by guest www.bloodjournal.org From Viability was assessed after treating DT40 cells with selinexor for 24 hours. Selinexor remains active in the presence of the BTK C481S mutation (Figure 2A) . To test our hypothesis in vivo, C57BL/6 mice were engrafted with CD19+CD5+ leukemia derived from ibrutinib-refractory Eµ-TCL1 mice. While these mice are not known to possess the C481S mutation, they maintain functionally resistant disease as a result of selective pressure from ibrutinib exposure, mimicking acquired resistance in patients. At leukemia onset, mice were randomized to receive vehicle, ibrutinib alone or selinexor alone. As 8 We are grateful to the patients who provided blood for the above-mentioned studies, research support from The Leukemia and Lymphoma Society in the form of a translational grant (SCORE LLS 7080-06/7004-11), and the National Cancer Institute (R01 5R01CA177292). We would like to thank Pharmacyclics Inc. for providing the ibrutinib for the in vivo studies and Karyopharm Inc. for providing selinexor used in these studies.
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